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Background: Some HIV-neutralizing antibodies have an antigen-binding site with dual specificity, for the plasma mem-
brane and a viral epitope.
Results: We engineered membrane affinity outside the antigen-binding site by conjugating cholesterol, with concomitantly
increased antiviral potency.
Conclusion: A natural mechanism dependent on affinity maturation is mimicked by conjugation of a lipid.
Significance: This is a general strategy to boost the potency of antiviral antibodies.
Thebroadly neutralizing antibodiesHIV2F5 and4E10,which
bind to overlapping epitopes in the membrane-proximal exter-
nal region of the fusion protein gp41, have been proposed to use
a two-step mechanism for neutralization; first, they bind and
preconcentrate at the viral membrane through their long,
hydrophobic CDRH3 loops, and second, they form a high affin-
ity complex with the protein epitope. Accordingly, mutagenesis
of the CDRH3 can abolish their neutralizing activity, with no
change in the affinity for the peptide epitope.We showhere that
we can mimic this mechanism by conjugating a cholesterol
group outside of the paratope of an antibody. Cholesterol-con-
jugated antibodies bind to lipid raft domains on the membrane,
and because of this enrichment, they show increased antiviral
potency. In particular, we find that cholesterol conjugation (i)
rescues the antiviral activity of CDRH3-mutated 2F5, (ii)
increases the antiviral activity of WT 2F5, (iii) potentiates
the non-membrane-binding HIV antibody D5 10–100-fold
(depending on the virus strain), and (iv) increases synergy
between 2F5 and D5. Conjugation can be made at several posi-
tions, including variable and constant domains. Cholesterol
conjugation therefore appears to be a general strategy to boost
the potency of antiviral antibodies, and, because membrane
affinity is engineered outside of the antibody paratope, it can
complement affinity maturation strategies.
The broadly neutralizing antibody (bnAb)3 2F5 is perhaps
the most extensively studied of all HIV antibodies. It binds to
the membrane-proximal external region (MPER) of the fusion
protein gp41 (1). TheMPER (residues 662–683) lies at the base
of the gp41 ectodomain, immediately proximal to the trans-
membrane domain; it is highly conserved and critical for viral
fusion (2). Another bnAb, 4E10, binds to an overlapping
epitope (3). A key feature of both antibodies is the presence of a
relatively long, hydrophobic CDRH3 loop, most of which does
not contact the peptide antigens in the crystal structures (3, 4)
and yet is essential for the antiviral activity (5, 6). In particular,
two independent studies have shown that mutagenesis of the
hydrophobic residues at the tip of the CDRH3 or ablation of the
apex of the same loop can completely abolish the neutralizing
activity of 2F5 and 4E10while inducing no change in the affinity
for the peptide epitope (5–8). The same studies have shown
that the CDRH3 residues promote binding of the antibodies to
synthetic lipid bilayers (6, 7), including liposomes that mimic
the lipid composition of the HIV-1 membrane (9).
These results have led to the proposal of a two-step mecha-
nism forHIVneutralization by 2F5 (5, 6) and 4E10 (6). In step 1,
the antibodies attach to the viral membrane through their long,
hydrophobic CDRH3 loops. This weak reversible binding pre-
concentrates the antibody on the virion surface until binding of
gp120 to CD4 and the chemokine coreceptor triggers the gp41
conformational change leading to formation of the prehairpin
intermediate, with the fusion peptide inserted into the target
cell membrane (10). As a consequence, during the relatively
short window of opportunity (estimated to be about 15 min
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(11)) before fusion is completed, the local concentration of the
antibody in the vicinity of the MPER epitope is much higher
than the bulk aqueous concentration, driving formation of a
high affinity complex (step 2), which prevents fusion from pro-
ceeding to completion.
An open question, with important practical implications, is
whether anMPER bnAb simply needs to possess the two proper-
ties or if a very specific geometry of the combining site is required,
aspresent in2F5and4E10.Tworecent studies seemtosupport the
latter hypothesis, proposing that the CDRH3 loop of 2F5 partici-
pates in a membrane-embedded “extended paratope” (12, 13). A
third study, however, questions this conclusion (13).
If the two-step hypothesis is true, one could imagine engi-
neering membrane affinity outside of the antibody paratope, in
FIGURE1.Chemistryused for conjugationof cholesterol to anantibody.Maleimido-PEG12-chol is conjugated to theunpaired cysteine residues introduced
in the antibody sequence.
FIGURE 2. Schematic representation of the cholesterol-conjugated antibodies. The WT residues are shown in black, whereas the mutated residues are
highlighted in red. Cholesterol is shown in violet. A, 2F5; B, D5.
Cholesterol-conjugated Antibodies
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this way making general the special mechanism of 2F5/4E10.
To address this issue, we have sought a general way to increase
the affinity of an antibody for lipid membranes without the
need of a special sequence in its CDRH3.
A substantial body of evidence supports the notion that viral
fusion occurs in confined areas of the interacting viral/host
membranes (14). For HIV, the lipid composition of the viral
membrane is strikingly different from that of the host cellmem-
brane, being particularly enriched in cholesterol and sphingo-
myelin (9, 15–17). Cholesterol and sphingolipids are often lat-
erally segregated inmembranemicrodomains or “lipid rafts” (9,
19).We have recently shown that the efficient targeting to lipid
rafts can be achieved by conjugation of a cholesterol group and
that this modification brings a dramatic increase in antiviral
potency of peptide fusion inhibitors derived from the heptad
repeat region of fusion proteins, including gp41 (20–25). Our
FIGURE 3.Analytical characterization of cholesterol-conjugated antibodies. Top, SDS-PAGE analysis. mAbswere separated by SDS-PAGE and stainedwith
Coomassie Brilliant Blue. Lane 1, 2F5[L100AS,F100BS,T20C]; lane 2, 2F5[L100AS,F100BS,T20C]-chol; lane 3, 2F5[S457C]-chol; lane 4, 2F5[L100AS, F100BS, S457C];
lane 5, 2F5[L100AS, F100BS, S457C]-chol; lane 6, D5[T20C]-chol; lane 7, D5[S444C]-chol. The heavy and light chains of each mAb are shown in the top (H) and
bottom (L) panels, respectively. Specific conjugation of the light chain resulted in the presence of higher molecular weight species (filled circle) in comparison
with the unconjugated light chain (open circle). Additional species (asterisk) were observed if the light chain was also nonspecifically conjugated. Bottom,
MALDI-TOF analysis of cholesterol-conjugated 2F5 and D5 antibodies.
Cholesterol-conjugated Antibodies
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findings have been independently confirmed (26). Conjugation
to sphingosine has also been shown to potentiate antiviral
activity (27). Importantly, cholesterol conjugation has been
shown to efficiently localize the much larger green fluorescent
protein to the membrane of living cells (28). Based on this, we
asked if conjugation of cholesterol to a previously described
CDRH3 mutant of 2F5, which is unable to neutralize HIV (5),
could rescue its antiviral activity. We show here that this is the
case and that cholesterol conjugation can also increase the anti-
viral activity of another HIV antibody, D5, which is devoid of
membrane affinity.
EXPERIMENTAL PROCEDURES
Cell Lines—Human embryonic kidney 293 cells (HEK 293
ATCC CCL1573) were grown in Dulbecco’s modified essential
medium (DMEM; Invitrogen) supplemented with 10% FBS.
HEK 293 EBNA cells (Invitrogen, catalogue no. R620-07) were
grown in DMEM with 10% FBS, 1% nonessential amino acids
(Invitrogen), and G418 (Invitrogen) at 0.25 mg/ml. The HEK
293T cell line was purchased from ECACC, and the HeLa
TZM-bl cell line was obtained through the Programme EVA
Centre for AIDS Reagents, National Institute for Biological
Standards and Control (NIBSC). Both were grown in DMEM
with 10% FBS and 1% nonessential amino acids. Monoclonal
antibodies were produced in HEK 293 EBNA cells cultured in
CDCHO medium (Invitrogen) supplemented with 100 M
hypoxanthine and 16 M thymidine (Invitrogen).
Generation of HIV-1 Pseudovirus—Human embryonic kid-
ney 293T/17 cells (ATCC: CRL-11268) (1.2 106) were seeded
in 10-cm2 dishes. After 24 h, cells were co-transfectedwith 2g
each of a pNL4.3 construct lacking env and an env pcDNA3.1
D-TOPO expression vector using Lipofectamine 2000 (Invitro-
gen). 72 h post-transfection, culture supernatants containing
pseudotype virus were filtered through 0.22-m filters and
stored at 4 °C.
Generation of Human Monoclonal Antibodies—All tested
mAbs were generated by subcloning of synthetic heavy and
light chain variable regions (GeneArt, Invitrogen) into two
eukaryotic vectors for the expression of heavy (IgG1 isotype)
and light chains, as described previously (29). These two plas-
mids were co-transfected into HEK 293 EBNA cells with Lipo-
fectamine 2000 reagent (Invitrogen), andwhole human IgGwas
purified from culturemediumwithHi-Trap protein A columns
(GE Healthcare).
Conjugation of Cholesterol to mAbs—Cholesterol-PEG12-
maleimide (compound 1 in Fig. 1) was obtained from Charn-
wood Molecular Ltd. (Loughborough, UK). To ensure reactiv-
ity of the free cysteines introduced in the mAb sequence, the
antibodies were incubated for 2 h at 37 °Cwith a 200-foldmolar
excess of L-cysteine in triethylamine buffer (pH8.0) inN2 atmo-
sphere. Reduced mAbs were buffer-exchanged into conjuga-
tion buffer (10 mM sodium phosphate, 5 mM EDTA, pH 7.2) on
PD-10 desalting columns (GEHealthcare). Next, octyl -D-glu-
copyranoside (Sigma) was added to themAbs solution to a final
concentration of 40 mM, and antibodies were reacted with a
10-fold molar excess of cholesterol-PEG12-maleimide for 2 h at
room temperature. mAbs were then bound to Protein A-Sep-
harose (Sigma) overnight at room temperature with constant
rotation in a vertical rotator. Bound mAbs were washed four
times with 20 resin volumes of 40 mM octyl -D-glucopyrano-
side in conjugation buffer, followed by four washing steps with
20 resin volumes of plain conjugation buffer. mAbs were eluted
from resin with 100 mM glycine-HCl (pH 2.7) and neutralized
with the addition of 1 M Tris-HCl (pH 9.0) to a final concentra-
tion of 100 mM. Eluted mAbs were buffer-exchanged into PBS
on PD-10 desalting columns (GEHealthcare). Conjugation effi-
ciencywas analyzed by 12%SDS-PAGEandmass spectrometry,
and the results were in good agreement.
Conjugation efficiency varied with the reaction conditions.
Although it was possible to fully derivatize the unpaired cys-
teine residue, driving conjugation to completion led to the
appearance of SDS gel bands corresponding to incorporation of
more than two maleimido-PEG12-chol molecules per antibody
FIGURE 4. Binding of 2F5 and D5 mAbs to gp41 peptides. Binding of
unconjugated and cholesterol-conjugated HIV-1 mAbs to the specific gp41
peptide antigen was analyzed by ELISA. 96-well plates were coated with
either peptide P1728 (for 2F5 antibodies) or peptide P2370 (for D5 antibod-
ies) and incubatedwith various concentrations ofmAb 2F5 (A) ormAbD5 (B).
Values on the vertical axis are absorbancemeasured at 405 nm.mAb concen-
tration is shown on the right (in nM). The experiments were performed in
duplicate, and the error bars represent S.D.
Cholesterol-conjugated Antibodies
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(confirmed by MS). Although maleimide-based reagents are
selective for free thiols at neutral pH, reaction with primary
amines has been documented at higher pH (30), and the pKa of
individual lysine residues can be influenced by structural and
environmental features (31).
Hence, it was decided to use the conditions reported above,
which led to the target antibody with two cholesterol groups
per molecule in the presence of residual unconjugated anti-
body. The percentage of conjugation varied from 50 to 70%.
For the experiments described here, the concentration of
cholesterol-conjugated antibody was adjusted based on the
SDS data. Because the difference in antiviral IC50 between the
cholesterol-conjugated/unconjugated antibodies was always
10-fold and typically 100-fold, the presence of residual
unconjugated antibody in the conjugated antibody sample was
considered irrelevant for the interpretation of results. The ana-
lytical data for the antibodies described here are reported in
Fig. 2.
Binding of HIV-1 mAbs to HEK 293 Cells—HEK 293 cells
(7.5  105) were incubated for 1 h at room temperature with
HIV-1 mAbs in phosphate-buffered saline (PBS) containing
0.2% bovine serum albumin (BSA) and 10 mM HEPES (fluores-
cence-activated cell sorter (FACS) buffer). mAb binding was
revealed by Fc-specific, allophycocyanin-conjugated goat
antihuman IgG. As a control, isotype-matched human IgG1
was used. FACS acquisitions and analyses were performedwith
a FACSCalibur (BD Biosciences) and CellQuest software.
Treatment with Cholesterol-depleting Agents—HEK 293 cells
were washed twice with serum-free DMEM and treated for 1 h
at 37 °C with 10 mM methyl--cyclodextrin (Sigma) diluted in
FIGURE 5. Cholesterol conjugation rescues the antiviral activity of CDRH3-mutated 2F5. Shown is antiviral activity of 2F5 (●), 2F5[L100AS,F100BS,T20C]
(f), 2F5[L100AS,F100BS,S457C] (Œ), 2F5[L100AS,F100BS,T20C]-chol (), and 2F5[L100AS,F100BS,S457C]-chol (‚) on HIV-1 strains HXB2 (A), JR-FL (B), and JR-CSF
(C). Antibodypreparationswere incubated at the indicated concentrationswithpseudotype virus before infecting TZM-bl cells. Infectionwasdetermined after
72 h by reading luminescence. Error bars, S.D.
Cholesterol-conjugated Antibodies
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serum-free DMEM. After incubation, cells were washed three
times with serum-free DMEM prior to flow cytometry (FACS)
assays.
HIV-1 Infectivity and Neutralization Assays—HeLa TZM-bl
cells (2 105) were seeded in 96-well Optilux plate (BD Biosci-
ences). After 24 h, pseudotype virus and 200l ofmediumwere
added and incubated at 37 °C in a humidified atmosphere con-
taining 5%CO2, for 72 h.Mediumwas then removed, cells were
lysed with 50 l of cell lysis buffer (Promega), and 50 l of
luciferase substrate (Promega) was added. Luminescence was
measured by using a BMG Labtech Optima plate reader. For
neutralization assays, pseudotype virus was mixed with dilu-
tions of mAbs, incubated for 1 h at 37 °C, and then added to
TZM-bl cells plated into a 96-well Optilux plate containing
100 l of medium, and the plates were incubated for 4 h before
an additional 100l of mediumwas added. Cultures were incu-
bated and read as for the infectivity assay. For cell binding
assays, dilutions of mAbs were added to TZM-bl cells plated
into a 96-well Optilux plate and incubated for 1 h at 37 °C. They
were then washed with PBS to remove unbound antibody, and
pseudotype virus was added. The plates were incubated for 4 h
before an additional 100 l of medium was added. Cultures
were incubated and read as for the infectivity assay.
Combination Experiment—Synergistic, additive, or antago-
nistic interaction by two antibodies for virus neutralization was
evaluated by the median effect analysis method, as described
(32), using the CompuSyn software (ComboSyn Inc., Paramus,
NJ). This approach takes the potency, shape, and slope of the
dose-dependent neutralization curve of each antibody into
account, both alone and in combination, at a constant ratio, to
calculate a combination index (CI). A CI value of1 indicates
synergism, 1 indicates an additive effect, and 1 indicates
antagonism. For each antibody, dose-dependent neutralization
was initially measured to determine a concentration range.
FIGURE 6. Cholesterol conjugation potentiates the antiviral activity of WT 2F5. Shown is antiviral activity of 2F5 (●), 2F5[L100AS,F100BS,S457C] (),
2F5[L100AS,F100BS,S457C]-chol (), and 2F5[S457C]-chol () on HIV-1 strains HXB2 (A), JR-FL (B), and JR-CSF (C). Error bars, S.D.
Cholesterol-conjugated Antibodies
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Neutralization values of serial 5-fold dilutions of each antibody
alone and in combination were then measured in a range of
concentrations above and below the IC50 values. Themeasured
neutralization values were entered into the program as frac-
tional effects in the range of 0.01 fractional effect 0.99 for
each of the two antibodies and for both in combination. The
software determines the linear correlation coefficient, r, of each
curve to indicate the fit or conformity of the datawith respect to
the median effect method and calculates the CI values in rela-
tion to fractional effect values. The cultures were incubated and
read as for the neutralization assay.
Mass Spectrometry—Prior to MALDI-TOF analysis, each
antibody (0.3mg/ml diluted in 50mM ammonium bicarbonate)
was reduced by the addition of 5 l of 0.2 M dithiothreitol
(DTT) for 30 min at 37 °C, followed by immediate cooling at
4 °C. MS analysis was performed on a MALDI-TOF micro MX
instrument (Waters Co., Manchester, UK) equipped with a
pulsed nitrogen laser (  337 nm). The instrument source
voltage was set to 12 kV. The pulse voltage was optimized at
1999 V, and the detector voltage was set to 5200 V. Measure-
ments were performed in the mass range m/z 20,000–80,000,
with a suppression mass gate set tom/z 3000 to prevent detec-
tor saturation frommatrix cluster peaks and an extraction delay
of 600 ns. Prior to acquisition of spectra, 1 l of reduced anti-
body solution was mixed with 1 l of saturated sinapinic acid
matrix solution (10 mg/ml in acetonitrile/water containing
0.1% trifluoroacetic acid (1:1.5, v/v)). A droplet (1 l) of the
resulting mixture was placed on the mass spectrometer’s sam-
ple target and dried at room temperature. After complete evap-
oration of the liquid, the sample was loaded into themass spec-
trometer and analyzed in positive acquisition linear mode.
External calibrationwaswith amixture of standard proteins (10
pmol/l each of insulin, cytochrome c, trypsinogen, and albu-
min; Sigma). Mass accuracy near the nominal value (300 ppm)
was achieved for each standard. All spectra were processed and
analyzed using MassLynx version 4.1 software (Waters, Mil-
ford, MA).
ELISA—The peptide antigens for the ELISA experiments
were prepared by standard Fmoc (N-(9-fluorenyl)methoxycar-
bonyl) solid-phasemethods. Peptide sequences were as follows:
P1728, Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-
Asn-Lys(N-biotin)-NH2; P2370, Ac-Ile-Glu-Lys-Lys-Ile-Glu-
Ala-Ile-Glu-Lys-Lys-Ile-Glu-Ala-Ile-Glu-Lys-Lys-Ile-Glu-Ala-
Ile-Glu-Lys-Leu-Leu-Gln-Leu-Thr-Val-Trp-Gly-Ile-Lys-Gln-Leu-
Gln-Ala-Arg-Ile-Leu-NH2. For ELISA with the biotinylated
HIV-1 antigen P1728, 96-well plates (Immunoplate Maxisorp,
Nunc) were precoated with 0.25 g/well streptavidin (Thermo
Scientific) in coating buffer (50mMNaHCO3, pH9.6) overnight
at 4 °C and washed four times with PBST buffer (0.05% Tween
20 in PBS). Plates were incubated for 2 h at room temperature
with 1 g/well P1728 in coating buffer, subsequently washed
with PBST buffer, and blocked for 1 h at 37 °C with 250 l/well
of milk buffer (5% milk in PBST). Plates were incubated with
various HIV-1 antibodies diluted in milk buffer overnight at
4 °C, washed, and incubated for 1 h at room temperature with
anti-human IgG Fc-specific AP conjugate (Sigma) diluted
1:10,000 in milk buffer. Alkaline phosphatase was revealed by
incubation with p-nitrophenyl phosphate substrate solution
FIGURE 7. Cholesterol conjugation potentiates the antiviral activity of
antibody D5. Shown are neutralization curves of D5 (E), D5[T20C]-chol and
D5[S444C]-chol (ƒ), and 2F5 (●) on HIV-1 strains HXB2 (A), JR-FL (B), and
JR-CSF (C). Error bars, S.D.
TABLE 1
Breadth of neutralization of cholesterol-conjugated antibodies
The antibodies shown are as follows. Ab1, 2F5; Ab2, 2F5[L100AS,F100BS,T20C]-
chol; Ab3, 2F5[L100AS,F100BS,S457C]-chol; Ab4, 2F5[S457C]-chol; Ab5, D5; Ab6,
D5[T20C]-chol; Ab7, D5[S444C]-chol.
Straina
IC50 of pseudotyped HIV strains
Ab1 Ab2 Ab3 Ab4 Ab5 Ab6 Ab7
g/ml
HXB2 0.01 0.19 0.02 0.02 10.83 0.49 0.05
JR-FL 8.42 7.86 3.78 1.87 100 100 46.78
JR-CSF 0.27 0.20 0.06 0.03 100 0.49 0.07
E21LnD43 4.48 10.01 1.36 1.06 100 6.80 0.97
E21LnD17 20.47 21.98 2.35 0.54 100 7.89 1.24
E21BrD9 9.67 5.56 1.72 1.33 100 7.52 1.87
E21BrD82 19.71 15.30 2.92 0.76 100 41.12 16.9
Km34BIR70 100 100 4.87 0.86 100 11.99 15.4
Km34SeR33 100 44.49 1.82 0.17 100 23.51 2.70
a Characterized recombinant gp160 used in the pseudotype infectivity assay; for
full phenotypic characterization, see Ref. 53. E21LnD17, clade B, coreceptor
CCR5; E21LnD43, clade B, coreceptor CXCR4; E21BrD9, clade B, coreceptor
CCR5; E21BrD82, clade B, coreceptor CCR5, macrophage-tropic; Km34BIR70,
clade U (env gene not corresponding to any described group M subtype), core-
ceptor CCR5; Km34SeR33, clade U, coreceptor CCR5, macrophage-tropic.
Cholesterol-conjugated Antibodies
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(Sigma). Results were expressed as the difference between
A405 nm and A620 nm, measured by an automated ELISA reader
(Envision 2102 Multilabel reader, PerkinElmer Life Sciences).
ELISAwith the non-biotinylated peptide P2370 was performed
with the same protocol, with the exception of the streptavidin
precoating step.
Graphs and Statistics—Graphs were prepared using Prism
version 5.0c or 6.0e (GraphPad Software Inc., La Jolla, CA) or
SigmaPlot version 12.0 (Systat Software Inc., San Jose, CA).
RESULTS
Conjugation of Cholesterol to 2F5—A suitablemethod to gen-
erate an antibody-cholesterol conjugate is through thiol-ma-
leimide chemistry, whereby a cysteine residue, either native or
engineered, is used for conjugation on the side of the antibody,
and a reactive maleimide group is used on the cholesterol moi-
ety (33) (Fig. 1). A number of studies have shown that surface
cysteines can be introduced in all domains of an antibody with-
out interference with the inter- and intrachain disulfide bonds
(33–36), giving us ample choice for the site of attachment.
Because of the symmetrical nature of antibodies, two choles-
terol groups are attached per antibody molecule.
Our initial choice fell on VL Thr20, which we mutated into
cysteine, because modeling suggested that it might enable ori-
ented, concomitant binding of cholesterol to the membrane
and the 2F5 paratope to gp41. In addition to the Thr203 Cys
substitution, we introduced the two mutations Leu100A3 Ser
and Phe100B3 Ser (Kabat numbering), which completely abol-
ish the ability of 2F5 to bind lipid bilayers and its antiviral
activity (5). The cholesterol-conjugated antibody 2F5[L100AS,
F100BS,T20C]-chol was prepared by reaction of maleimido-
PEG12-cholesterol with 2F5[L100AS,F100BS,T20C] according
to the general scheme shown in Fig. 1. A schematic representa-
tion of this antibody together with the others discussed in the
paper is given in Fig. 2. The analytical data for the antibody are
shown in Fig. 3. After ensuring that 2F5[L100AS,F100BS,
T20C]-chol retained binding to its peptide epitope (Fig. 4A), we
tested it for antiviral activity on the highly sensitive HXB2 and
FIGURE 8. Cholesterol conjugation provides affinity for cholesterol-rich cell membranes. Binding of cholesterol-conjugated antibodies to HEK 293 cells,
measured by flow cytometry. Values on the vertical axis are mean fluorescence intensities (MFI), and the concentrations of mAbs (nM) used in the experiment
are shown in the top right corner of each panel. A, binding of 2F5, 2F5[L100AS,F100BS,T20C], 2F5[L100AS,F100BS,S457C], 2F5[L100AS,F100BS,T20C]-chol,
and 2F5[L100AS,F100BS,S457C]-chol to HEK 293 cells. B, binding of D5, D5[T20C]-chol, and D5[S444C]-chol to HEK 293 cells. C, binding of 10 nM
2F5[L100AS,F100BS,T20C]-chol to HEK 293 cells is reduced by pretreatment with methyl--cyclodextrin (MCD). Error bars, S.D.
Cholesterol-conjugated Antibodies
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the more resistant JR-FL and JR-CSF strains (Fig. 5). Choles-
terol conjugation was able to completely rescue the antiviral
activity abolished by the L100AS and F100BS mutations; on
all three strains tested, 2F5[L100AS,F100BS,T20C]-chol was
as potent as 2F5, whereas the control antibodies 2F5-
[L100AS,F100BS] and 2F5[L100AS,F100BS,T20C] were, as
expected, inactive.
The choice of Thr20 was a conservative one,motivated by the
suggestion that oriented binding is important for the mechan-
ics of the 2F5 CDRH3 (5, 12–13), a feature that is not required
by the proposed two-step mechanism (5, 6). To explore choles-
terol conjugation at a distant position from the antibody
paratope, we chose Ser457 in the CH3 domain of the heavy chain
(Fig. 2A). 2F5[L100AS,F100BS,S457C]-chol was prepared by the
same procedure used for 2F5[L100AS,F100BS,T20C] (Fig. 3).
2F5[L100AS,F100BS,S457C]-chol maintained binding to the
peptide epitope (Fig. 4A).When tested for antiviral activity (Fig.
5), it was only slightly less potent than 2F5[L100AS,F100BS,
T20C]-chol and 2F5. The control unconjugated antibody
2F5[L100AS,F100BS,S457C] was, as expected, inactive.
We next asked the question of whether cholesterol conjuga-
tion can synergize with the action of the CDRH3. If the 2F5
CDRH3 does indeed participate in an “extended paratope” (12,
13), selection must have optimized its properties along the
entire reaction coordinate rather than simply maximizing its
membrane binding capacity. It would follow that an additional
membrane-binding component might add to antiviral activity.
To address this question, we compared the antiviral potency of
FIGURE 9. Binding of cholesterol-conjugated antibodies is stable to cell washing. Shown are neutralization curves of 2F5 (E), D5 (), D5[S444C] (‚), and
D5[S444C]-chol (ƒ) onHIV-1 strainsHXB2 (A), JR-FL (B), and JR-CSF (C). Antibodypreparationswere incubated at the indicated concentrationswith TZM-bl cells
for 1 h. Cells were washed thoroughly with PBS, and pseudotype virus was added to cells. Infection was determined after 72 h by reading luminescence. Data
are presented as a percentage of uninhibited control. All reactions were performed in triplicate. Error bars, S.D.
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2F5; 2F5[L100AS,F100BS,S457C]-chol, featuring cholesterol
and amutatedCDRH3; and 2F5[S457C]-chol, featuring choles-
terol and aWTCDRH3 (Fig. 2A). When tested against the HIV
strain JR-FL, 2F5[S457C]-chol showed dramatically increased
potency versus 2F5 and the control antibody 2F5[L100AS,
F100BS,S457C] (Fig. 6).
Our results suggest that the antiviral activity of 2F5 (and
probably 4E10) requires both dual-binding affinity and
“extended paratope”; such a complex mechanism would justify
the need for extensive somatic affinity maturation during an
extended period of antigen exposure (37). More importantly,
these results show that cholesterol conjugation can replace and
actually improve upon the naturalmembrane-binding function
of the 2F5 CDRH3.
Cholesterol Conjugation Potentiates the Non-membrane
Binding HIV Antibody D5—The finding that cholesterol conju-
gation can provide additional binding energy to 2F5, without
conflict with its special binding mechanism, suggests that it
should work for other neutralizing antibodies. Therefore, we
explored cholesterol conjugation of the HIV nAb D5, whose
mechanism of action is well described and does not entail affin-
ity for the viral or cell membrane (38). D5 binds to a highly
conservedhydrophobic pocket in theN-heptad repeat region of
gp41, which is critical for the assembly of the postfusion 6-helix
bundle structure (39). It neutralizes a diverse range of HIV iso-
lates but is considerably less potent than 2F5. D5 therefore rep-
resented an ideal case to test whether cholesterol conjugation
would provide a more potent antiviral.
Also in this case, the VL position Thr20 and the CH3 position
Ser444 appeared suitable for cholesterol derivatization.D5[T20C]-
chol andD5[S444C]-cholwere prepared by the sameprocedure
used for the cholesterol-conjugated 2F5 antibodies (Figs. 2B
and 3).
Like the 2F5 antibodies, D5[T20C]-chol andD5[S444C]-chol
maintained binding to their peptide epitope (Fig. 4B). Both cho-
lesterol-conjugated D5 antibodies were able to inhibit all three
HIV strains, whereas D5 was only active on HXB2 (Fig. 7). On
the latter strain, D5[T20C]-chol and D5[S444C]-chol were
10-fold and 100-fold more potent, respectively, than WT D5.
The lack of activity of WT D5 on strains JR-CSF and JR-FL
was expected based on our previous data (IC50  1 M (38)),
and the neutralization observed for D5[T20C]-chol and
D5[S444C]-chol indicates that cholesterol conjugation may
increase the breadth of neutralization of this antibody. We
extended this analysis to six more HIV strains that are insensi-
tive to D5 neutralization and found that to a different degree,
they all became sensitive to the two cholesterol-conjugated
antibodies (Table 1).
In the same experiment, we also compared conjugated and
unconjugated 2F5 (Table 1). These data confirm that conjuga-
FIGURE 10. Effect of mAb combinations in neutralizing JR-CSF. A, neutralization curves of 2F5 (●), D5 (E), and 2F5  D5 () at constant ratios. B,
neutralization curves of 2F5 (●), D5[S444C]-chol (ƒ), and 2F5  D5[S444C]-chol () at constant ratios. C, neutralization curves of D5 (E),
2F5[L100AS,F100BS,S457C]-chol (‚), and D5 2F5[L100AS,F100BS,S457C]-chol () at constant ratios. D, D5 (E), 2F5[S457C]-chol (), and D5 2F5[S457C]-
chol (). Antibodypreparationswere incubatedat the indicated concentrationswithpseudotypevirusbefore infectingTZM-bl cells. Infectionwasdetermined
after 72 h by reading luminescence. Data are presented as a percentage of uninhibited control. All reactions were performed in triplicate. E, CI values for
combinations of 2F5 and D5 with D5[S444C]-chol, 2F5[L100AS,F100BS,S457C]-chol, or 2F5[S457C]-chol at ED50, ED75, ED90, and EC95, as computed by Com-
puSyn. For each set of analyses, the linear correlation coefficient rwas0.88, indicating a good fit to the plots (data not shown). A CI of1 is synergism, and
a CI of1 is antagonism. Error bars, S.D.
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tion can rescue (in position Thr20) and actually potentiate
(in position Ser457) the antiviral activity of the inactive
2F5[L100AS,F100BS] mutant and can work in concert with the
natural membrane-binding CDRH3 to produce a superpotent
antibody (80–100% inhibition at 2 g/ml for 5 of 6 strains).
Notably, D5[T20C]-chol showed potency comparable with
that of WT 2F5 on all of the strains tested (Table 1). We may
conclude that cholesterol conjugation can evolve a weak nAb
with limited breadth of neutralization (38) into a potent bnAb
on a par with 2F5.
Cholesterol-conjugated Antibodies Bind to HumanCells—To
probe the mechanistic basis of cholesterol conjugation, we
tested binding of cholesterol-conjugated antibodies toHEK293
cells.We had previously shown that the cholesterol-conjugated
antiviral peptides bind to and concentrate on the cell surface
(21). Likewise, cholesterol conjugation endows both 2F5 and
D5 antibodies with high affinity for human cells (Fig. 8, A and
B). Binding is strongly reduced by cell treatment with methyl-
-cyclodextrin, which depletes cholesterol and leads to disor-
ganization of lipid raft microdomains (40) (Fig. 8C).
Importantly, as observed for the cholesterol-conjugated pep-
tides (21), binding of cholesterol-conjugated D5 is stable to cell
wash prior to virus addition (Fig. 9). Interestingly, the lipid raft-
binding CDRH3 ofWT2F5 also provides this property, albeit to a
lower degree than cholesterol conjugation, as judged by the resid-
ual ability of 2F5 to neutralize strains HXB2 and JR-FL after cell
wash (Fig. 9).
Synergy between Cholesterol-conjugated HIV Antibodies—
The combination of 2F5 andD5 is known to be synergistic (41),
and we asked if this synergy is maintained for the correspond-
ing cholesterol-conjugated antibodies. We tested a number of
combinations of unconjugated and cholesterol-conjugated 2F5
and D5 on HIV strain JR-CSF and observed synergy in all cases
(Fig. 10). The most notable finding was that synergy of the nat-
urally membrane-binding bnAb 2F5 with the non-membrane
binding nAb D5 was increasedwhen the latter was made mem-
brane-binding via cholesterol conjugation. We may conclude
that cholesterol conjugation, which independently potentiates
each antibody, also potentiates their combination.
DISCUSSION
Wehave shown here that the site-specific addition of choles-
terol to anHIV antibody endows it with affinity for the lipid raft
domain of the cell membrane and, because of this enrichment,
potentiates the antibody-neutralizing activity. The data for D5
in particular illustrate the advantage of cholesterol conjugation
because an antibodywith limited potency and breadth becomes
similar to the bnAb 2F5. This enhancement is independent of
the specific epitope and therefore represents away to generalize
the agreed upon mechanism of binding of the HIV bnAbs 2F5
FIGURE 11. Schematic representation of engineered polyreactivity. A, a monoreactive antibody cannot display homotypic bivalent binding for the low
density of target epitopes on the pathogen surface. Pathogen protein is shown in dark orange, the heavy chain of mAb is shown in shades of green, and light
chain is shown in pink. B, a polyreactive antibody can display heterotypic bivalent binding through heteroligation of the protein epitope and the pathogen
membrane. The polyreactive paratope is highlighted in red. C andD, engineering polyreactivity in amonospecific antibody. Shown is heteroligation of protein
epitope and pathogen membrane through the cholesterol anchor (violet) conjugated to the variable (C) or constant (D) domain of the antibody.
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and 4E10, where the lipid binding sequence is present in the
long CDRH3 of their paratope (37). This mechanism seems
valid also for the MPER-binding antibody 10E8, initially
described as an exception because of its exceptional neutraliza-
tion potency without intrinsic affinity for membranes (42) but
later shown to actually bind lipid bilayers through two hydro-
phobic residues in its CDRH3. In the latter work, Chen et al.
(43) hypothesized that the superior neutralization potency of
10E8 versus 4E10 is related to its differential affinity for choles-
terol-rich domains and membranes in general; such a mecha-
nism would resemble the lipid raft-targeting effect of choles-
terol conjugation.
Our findings may be relevant to the proposed role of polyre-
activity, the ability of an antibody to recognize more than one
unrelated antigen, in the natural response to HIV. It has been
argued that for HIV, which displays its trimeric gp140 envelope
spikes at very low density (44–46), monospecific bivalent bind-
ing is not possible (47). A polyreactive antibody, with both high
affinity binding to a virus-specific site and low affinity binding
to a secondary site on the virion and/or the target cell, may
engage in bispecific bivalent interaction (also called heteroliga-
tion). 2F5 and 4E10 would then represent special cases of poly-
reactivity. Accordingly, the majority of HIV antibodies with
high neutralizing activity isolated frommemory B cells of HIV-
infected patients were found to be polyreactive (47).
Our data support this hypothesis by showing that when a
non-membrane-binding antibody (D5) ismade polyreactive, its
antiviral potency increases. An illustration of this “engineered
polyreactivity” via cholesterol conjugation is given in Fig. 11.
Additionally, we found that there is increased synergism
between the two cholesterol-conjugated, polyreactive antibod-
ies 2F5 and D5 versus their natural variants, suggesting that a
polyclonal polyreactive response, as naturally found in HIV-
infected patients (47), may be particularly effective.
The scope of cholesterol conjugation remains to be estab-
lished for antibodies to viruses other than HIV and even for
other HIV antibodies. Although one would expect the magni-
tude of the effect to bemaximal for fusion-inhibitory antibodies
like 2F5/4E10, the preconcentration effect from additional
membrane affinity might also benefit receptor-binding nAbs
like b12 (which binds to the CD4-binding site) or PG9 (which
binds the membrane-distal apex of the spike). It appears likely
that the optimal conjugation position and linker length will
be antibody-specific, although the possibility of engineering the
constant region may attenuate the need for case-by-case
optimization.
On the practical side, cholesterol conjugationmay find appli-
cation in the development of antibody therapeutics. Increased
in vitro potency has been shown to correlate with in vivo effec-
tiveness (48) and is usually achieved via affinity maturation or
structure-based design (48). These approaches typically
improve the koff component of KD and may work in concert
with cholesterol conjugation, which improves the kon compo-
nent. The success of cholesterol conjugationwithD5 is encour-
aging because, in this case, affinity maturation failed to identify
variants more potent than the parental nAb (49).
Cholesterol may represent a hapten and elicit the formation
of anti-drug antibodies, which would limit the efficacy of
chronic (but not acute) administration of a cholesterol-conju-
gated antibody. However, the clinical experience so far with
antibody-drug conjugates (50) has not identified anti-drug anti-
bodies as a major issue.
Finally, the advantage of cholesterol conjugation might
extend beyond antiviral antibodies. Lipid rafts are a general
membrane-organizing principle, and several receptors have
been described to concentrate in the “raft phase” (51). Accor-
dingly, we showed that conjugation of cholesterol to the pep-
tide hormone oxyntomodulin, a co-agonist of the GLP-1 and
glucagon receptors with antidiabetic and anti-obesity activity,
produced a substantial increase in biological potency (18, 52).
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